Disruption in combination inhaled corticosteroid therapy may lead to an increased rate of costly exacerbations and hospitalizations for Medicare patients

(American College of Chest Physicians) Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news